Kleinerman Laboratory

Principal Investigator

Eugenie S. Kleinerman, M.D., is a tenured Professor in the Division of Pediatrics and the Department of Cancer Biology. She is board-certified in pediatrics and holds the Mary V. and John A. Reilly Distinguished Chair. Dr. Kleinerman joined MD Anderson in 1984. She rose through the ranks from Assistant Professor to Professor, before becoming the first woman to lead a clinical Division at MD Anderson as Division Head of the Division of Pediatrics from 2001 to 2015.

Dr. Kleinerman is internationally recognized for her scientific and clinical expertise in sarcomas, particularly osteosarcoma (OS). She pioneered the use of a unique immunotherapy agent, liposome-encapsulated MTP-PE, for children with unresponsive relapsed osteosarcoma lung metastases. Kleinerman’s pioneering use of this immunotherapeutic agent in children with osteosarcoma resulted in the first improvement in long term survival of children with this disease in over 25 years.

Dr. Kleinerman’s research program has been funded by the NCI for over 22 years. Her research also focuses on understanding the mechanisms involved in osteosarcoma metastasis to the lung. Most recently, her research has focused cardio-oncology and using exercise interventions to decrease the acute and late cardiotoxic effects of Doxorubicin.

Dr. Kleinerman has served on numerous NCI study sections and was a prior member of an U.S. Food and Drug Administration (FDA) advisory panel. She has authored more than 210 articles and 23 book chapters. She is the editor of the book "Current Advances in Osteosarcoma" published in 2014 and its second edition published in 2020. She has mentored numerous graduate students, postdoctoral fellows, M.D./Ph.D. students, and physician-scientists and has worked to promote women and women’s issues in academic medicine.

Learn more about Eugenie S. Kleinerman, M.D.